ShiPing Zou, Ph.D

US Citizen

** *** **** **., ********, MA 02052

Tel: 804-***-****; Email: adchdx@r.postjobfree.com

https://www.linkedin.com/in/shipingzou/

https://scholar.google.com/citations?user=w9b9V2YAAAAJ&hl=en

Summary

Creative and detail-oriented team leader with excellent critical thinking and multi-tasking skills, plus 15+ years academic and industry experience and proven ability to manage high throughput product development team. A passionate neuroscientist with in-depth training in cell-based models in studying HIV-induced neurodegeneration and inflammation, neuron-glial interaction and drug abuse.

Key skill/experience:

ISO13485 standards, GLP/GMP Guidelines

4 years of biotech industry experience, with 3 years leading high throughput R&D team.

8 Years of Academic research lab management experience

Product/Project Management

20+ Publication of original scientific work in high-quality journals

Process Development/Improvement/Validation

Strategic planning & Critical thinking

Excellent Presentation/Communication skills

Leadership/Management/Team building

Customer-centric product development and Roadmap planning

Neurodegeneration/Neuroinflammation

Aseptic Techniques

Stem Cell Technique/Cell Line Technique

Cell-Based Assay Development

Human/Murine primary cell culture

In vitro & in vivo models

Murine brain surgery

Analytical and problem-solving skills

Microscopy (Fluorescence, Confocal, Electron)

Multitasking and Fast Learning

DNA/RNA Techiniques (KO/KD/siRNA/PCR etc.)

Molecular and Cellular biology techniques

Immunohistochemistry/Immunofluorescence

Ca2+ imaging/Cell Staining

Key accomplishments

3 years of experience in Customer-centric product development, from Roadmap planning, Target Identification, Concept Development to Product Development and Market Launch.

Heavily involved in promoting neuroscience marketing/sales in China - helped achieve double digit growth on sales of neuroscience products in China for two continuous years.

Leading effort in developing, optimizing, characterizing and validating 500+ antibody- & recombinant protein-based products since 2016, which results in release of 200+ products.

Led the project to establish a stage-gate product development process that is fully compliant to ISO13485 quality standard for new product verification/validation including IVD products.

In first year of leadership in biotech, gained efficiencies that resulted in more than 2x output from PD team without additional headcount.

Key members of several kaizen and continuous improvement processes, including a company-wide Kaizen practice that greatly improves the efficiency of in house hybridoma development procedure.

Education and Training

Ph.D. -Neuroscience, Virginia Commonwealth University, Richmond, VA (2015)

M.S. -Biological Science (Molecular Biology), University of Kentucky, Lexington, KY (2003)

M.S. -Computer Science, University of Kentucky, Lexington, KY (2003)

B.S. -Genetics and Genetic Engineering, Fudan University, Shanghai, China (1999)

Professional Experience

BioLegend Inc. – hold positions of increasing responsibility ultimately leading a productive and efficient PD team (4 scientists + 4 research associates)

Product Development Manager (Sep. 2019 – Present)

Product Development Supervisor (Jun. 2017 – Aug. 2019)

Scientist, Neuroscience (Jun. 2016 – May 2017)

Responsibilities & accomplishments

Responsible for management of neuroscience R&D team, including strategic planning of research roadmaps, talent acquisition, portfolio management, and product development and release.

Establish quality product development process that is fully compliance to ISO13485 standard.

Instrumental in setting up roadmaps in key research areas to strategically expand the neuroscience portfolio.

Allocate resources and streamline processes to increase the efficiency and capacity of the PD team without compromising quality.

Leading effort in developing, characterizing and validating 500+ antibody & recombinant protein projects, which results in release of 200+ products in 3.5 years.

Build and foster relationships with external and internal collaborators.

Heavily involved in promoting neuroscience marketing/sales in China - helped achieve double digit growth on sales of neuroscience products in China for two continuous years.

Promote company brand exposure in neuroscience field

R&D Technical Projects & Experiences

With limited budget and resources, developed KO/KD platforms with various cell lines (HeLa, A549, etc.) using siRNA technique to characterize antibody specificity.

Creatively established a primary murine culture system used by the Neuroscience R&D team to validate cellular and synaptic markers.

Design, establish and optimize SOPs to circumvent the difficulties of lacking animal facility on site.

Create video protocol to train animal facility technician at a remote site on murine surgery/brain dissection.

Establish industry standard processes compliant to ISO 19485 quality standard.

Heavily involved in development of iPSC platform for antibody characterization and validation.

Strategically planned and placed iPSC platform as one of the key R&D projects for 2019.

Involved in business agreement/MTA of acquiring stem cells from a dependable commercial resource.

Hands-on experience on expanding/passage/cryopreservation of iPSCs, and induction of iPSCs to primary human neuronal cells.

Instrumental in drafting/finalizing key SOPs and working processes such as immunogen design, high throughput TCS screening, etc.

Virginia Commonwealth University

Postdoctoral Fellow (Jan. 2016 – May 2016)

Ph.D. Trainee/Research Assistant (Aug. 2011 – Dec. 2015)

Thesis: Effects of HIV and viral protein Tat on the viability and phenotype/function of oligodendroglial cells.

Lab and Research Specialist (Aug. 2007 – July 2011)

Toxic interactions between opiates and HIV viral proteins in Striatal Neurons (2007-2010)

University of Kentucky

Research Technician (Apr. 2003 – July 2007)

Research projects:

Role of the phosphatase and tensin homologue on chromosome 10 (PTEN) in mediating envelope glycoprotein 120 (gp120)-induced neurotoxicity in the striatum (2004-2006)

Effects of HIV-1 Tat and opiates on transcription factor activity in astrocytes(2004-2006)

A computation algorithm for protein secondary structure prediction (2001-2004)

Professional Affiliations

Industry Liaison, YIAC (Young Investigator’s Advisory Committee), American Society for Neurochemistry (2019 - Present)

Ad hoc committee member, YIAC (Young Investigator’s Advisory Committee), American Society for Neurochemistry (2016 - 2019)

Initiated and established the BioLegend travel award for ASN

Grant Review Specialist, Geriatric Training and Education Award (GTE Award), Virginia Center on Aging (2014)

Grant Review Specialist, Alzheimer’s and Related Disease Research Award Fund (ARDRAF) (2014)

Graduate Assistant, Alzheimer’s and Related Disease Research Award Fund (ARDRAF) (2013)

Research Grant

1F31NS084838-01A1 Zou (PI) FY 2014 – FY 2015 NIH/NINDS

“HIV-1 disrupts oligodendrocyte functions: Ca2+ mediated mechanisms”

Role: Principal Investigator

Selected Professional Honors

C.C.Clayton Award, Virginia Commonwealth University, 2014

Phi Kappa Phi Honor Society, 2013

Invited Talks

1.Zou S, Fuss B, Hauser KF, Knapp PE. Stage-specific effects of HIV-1 Tat on the viability and phenotype of oligodendroglia: interactions with glutamatergic receptors activate CaMKIIβ and GSK3β. (The Virginia Symposium on Brain Immunology and Glia, Charlottesville, VA. 2014)

2.Zou S, Fuss B, Hauser KF, Knapp PE. Glutamate receptors and calcium signaling through CaMKIIβ mediate effects of HIV-1 Tat on the viability and phenotype of oligodendroglia. (Virginia Universities AIDS Research Consortium, Richmond, VA. 2014)

Selected Publications (For completed list of publications, please refer to my google scholar page)

1.Zou S, Balinang JM, Paris JJ, Hauser KF, Fuss B, Knapp PE. Effects of HIV-1 Tat on oligodendrocyte viability are mediated by CaMKIIβ-GSK3β interactions. J Neurochem. 2019

2.Wheeler NA, Fuss B, Knapp PE, Zou S. HIV-1 Tat Inhibits Autotaxin Lysophospholipase D Activity and Modulates Oligodendrocyte Differentiation. ASN Neuro 2016

3.Zou S, Fuss B, Fitting S, Hahn YK, Hauser KF, Knapp PE. Oligodendrocytes Are Targets of HIV-1 Tat: NMDA and AMPA Receptor-Mediated Effects on Survival and Development. J Neurosci. 2015

4.Zou S, Hauser KF and Knapp PE. Glutamate receptors mediate stage-specific effects of HIV-1 Tat on the viability and phenotype of oligodendroglia. J. Neurovirology, 2013 volume 19 supplement 1: p.s94-s95

5.Podhaizer EM*, Zou S*, Fitting S, Samano KL, El-Hage N, Knapp PE, Hauser KF.Morphine and gp120 Toxic Interactions in Striatal Neurons are Dependent on HIV-1 Strain. J Neuroimmune Pharmacol, 2012.

6.Zou S, Fitting S, Hahn YK, Welch SP, El-Hage N, Hauser KF, Knapp PE. Morphine potentiates neurodegenerative effects of HIV-1 Tat through actions at µ-opioid receptor-expressing glia, Brain, 2011.

7.Zou S, El-Hage N, Podhaizer EM, Knapp PE, Hauser KF. PTEN gene silencing prevents HIV-1 gp120IIIB-induced degeneration of striatal neurons. J. Neurovirol. 2011.

Contact this candidate